CommercialCoverageMedium impact
08.00.85s, Tocilizumab and Related Biosimilars for Intravenous Infusion
Independence Blue Cross·Rheumatology, Oncology, Internal Medicine·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This policy update covers tocilizumab and related biosimilars for intravenous infusion under the pharmacy category. The policy was recently posted and will take effect April 1, 2026, but specific details about coverage changes, prior authorization requirements, or billing modifications are not provided in the available content.
Action Required
By April 1, 2026: Billing team should review the full policy document at the provided URL to understand specific changes to tocilizumab and biosimilar coverage requirements. Update billing procedures and prior authorization workflows as needed based on the complete policy details.